RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal
Rani Therapeutics Holdings, Inc. is finishing November with quieter headlines but still very lively trading. As of today, 28 November 2025, the biotech micro‑cap is consolidating after its spectacular October surge on the back of a transformative collaboration with Japan’s Chugai Pharmaceutical and a $60.3 million private placement that extended its cash runway into 2028. Reuters+2Stock Titan+2
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In
Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains.
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know
Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market open tipranks.com. The stock, which had closed at just $0.47 the prior day, briefly hit approximately $1.37 per share – nearly a 3× gain in value google.com. By midday, shares were still trading around the $1.30 level, up almost +180% on the day. This stunning one-day move snapped RANI out of penny-stock territory and back above the Nasdaq’s $1 minimum bid price, easing near-term delisting fears.
Tariff Shock and Fed Jitters: Asian Markets Stumble as Rally Meets Reality
Asian markets were mostly steady on Thursday as investors navigated mixed signals from central banks and awaited key U.S. data releases. Japan’s Nikkei 225 edged up 0.3% to 45,755, recovering from early losses abcnews.go.com. Optimism in Tokyo was underpinned by hopes that the Bank of Japan would maintain its ultra-easy policy: fresh data showed Tokyo consumer inflation at 2.5% in September, below forecasts abcnews.go.com. While still above the BoJ’s 2% target, the cooler-than-expected price rise eased pressure for immediate tightening. This spurred bets that the BoJ will hold off on rate hikes for now, weakening the yen and boosting exporter stocks investing.com investing.com. Japanese indexes remain near multi-decade highs on this dovish outlook investing.com.
The State of AI: Agentic Revolution, Healthcare Breakthroughs & Global Governance / Updated: 2025, July 8th, 12:00 CET
In the United States, more than 777 FDA-cleared AI devices are in clinical use for medical imaging, slashing scan times and flagging urgent cases. Microsoft’s MAI-DxO AI system achieves up to 85.5% diagnostic accuracy, vastly outperforming doctors at about 20%. Chugai Pharmaceutical and Gero announced a $1B+ collaboration to discover targets for age-related diseases using Gero’s AI platform. Meta Platforms recruited Apple’s Ruoming Pang, head of foundational models, in a multi‑million‑dollar deal, while Meta maintains over $55 billion in cash reserves for AI investments. Ford Chairman Jim Farley warned that AI could eliminate up to half of white-collar jobs, a
TechStock² Updates
